Literature DB >> 25377170

T. Kishi and N. Iwata: Varenicline for smoking cessation in people with schizophrenia: systematic review meta-analysis.

A Eden Evins1, L Elliot Hong, Deanna L Kelly.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2014        PMID： 25377170      PMCID： PMC5025253          DOI： 10.1007/s00406-014-0556-y

Source DB:  PubMed          Journal:  Eur Arch Psychiatry Clin Neurosci        ISSN： 0940-1334            Impact factor:   5.270


× No keyword cloud information.
  9 in total

1.  Effects of moderate-dose treatment with varenicline on neurobiological and cognitive biomarkers in smokers and nonsmokers with schizophrenia or schizoaffective disorder.

Authors:  L Elliot Hong; Gunvant K Thaker; Robert P McMahon; Ann Summerfelt; Jill Rachbeisel; Rebecca L Fuller; Ikwunga Wonodi; Robert W Buchanan; Carol Myers; Stephen J Heishman; Jeff Yang; Adrienne Nye
Journal:  Arch Gen Psychiatry       Date:  2011-08-01

2.  Maintenance treatment with varenicline for smoking cessation in patients with schizophrenia and bipolar disorder: a randomized clinical trial.

Authors:  A Eden Evins; Corinne Cather; Sarah A Pratt; Gladys N Pachas; Susanne S Hoeppner; Donald C Goff; Eric D Achtyes; David Ayer; David A Schoenfeld
Journal:  JAMA       Date:  2014-01-08       Impact factor: 56.272

3.  Adjunctive varenicline treatment with antipsychotic medications for cognitive impairments in people with schizophrenia: a randomized double-blind placebo-controlled trial.

Authors:  Joo-Cheol Shim; Do-Un Jung; Sung-Soo Jung; Young-Soo Seo; Deuk-Man Cho; Ji-Heon Lee; Sae-Woom Lee; Bo-Geum Kong; Je-Wook Kang; Min-Kyung Oh; Sang-Duk Kim; Robert P McMahon; Deanna L Kelly
Journal:  Neuropsychopharmacology       Date:  2011-11-02       Impact factor: 7.853

4.  Varenicline for smoking cessation in people with schizophrenia: a double blind randomized pilot study.

Authors:  Elaine Weiner; Alison Buchholz; Agnes Coffay; Fang Liu; Robert P McMahon; Robert W Buchanan; Deanna L Kelly
Journal:  Schizophr Res       Date:  2011-03-04       Impact factor: 4.939

5.  A randomized, double-blind, placebo-controlled study evaluating the safety and efficacy of varenicline for smoking cessation in patients with schizophrenia or schizoaffective disorder.

Authors:  Jill M Williams; Robert M Anthenelli; Chad D Morris; Joan Treadow; John R Thompson; Carla Yunis; Tony P George
Journal:  J Clin Psychiatry       Date:  2012-05       Impact factor: 4.384

Review 6.  Interventions for smoking cessation and reduction in individuals with schizophrenia.

Authors:  Daniel T Tsoi; Mamta Porwal; Angela C Webster
Journal:  Cochrane Database Syst Rev       Date:  2013-02-28

Review 7.  Varenicline for smoking cessation in people with schizophrenia: systematic review and meta-analysis.

Authors:  Taro Kishi; Nakao Iwata
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2014-10-05       Impact factor: 5.270

8.  Patterns of tobacco-related mortality among individuals diagnosed with schizophrenia, bipolar disorder, or depression.

Authors:  Russell C Callaghan; Scott Veldhuizen; Trincy Jeysingh; Chloe Orlan; Candida Graham; Gwen Kakouris; Gary Remington; Jodi Gatley
Journal:  J Psychiatr Res       Date:  2013-09-27       Impact factor: 4.791

9.  Use of varenicline for smoking cessation treatment in UK primary care: an association rule mining analysis.

Authors:  Yue Huang; Sarah Lewis; John Britton
Journal:  BMC Public Health       Date:  2014-10-02       Impact factor: 3.295
  9 in total
  1 in total

1.  Efficacy and Safety of Varenicline for Smoking Cessation in Schizophrenia: A Meta-Analysis.

Authors:  Saeed Ahmed; Sanya Virani; Vijaya P Kotapati; Ramya Bachu; Mahwish Adnan; Ali M Khan; Aarij Zubair; Gulshan Begum; Jeevan Kumar; Mustafa Qureshi; Rizwan Ahmed
Journal:  Front Psychiatry       Date:  2018-09-19       Impact factor: 4.157
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.